KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group
Kidney Int. 2022;102(5S):S1-S127.
Leggi
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease – analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin
Corbin KD, Dagogo-Jack S, Cannon CP, et al.
Diabetes Obes Metab. 2022 Nov 17.
Leggi
The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes
Ferrannini E, Mari A, Monaco GSF, et al.
Diabetologia. 2022 Dec 2.
Leggi
A randomized crossover pilot study evaluating glucose control during exercise initiated 1 or 2h after a meal in adults with type 1 diabetes treated with an automated insulin delivery system.
Myette-Cote E, Molveau J, Wu Z, et al.
Diabetes Technol Ther. Pub. online 18 Nov 2022.
Leggi
Mediating effects of technology-based therapy on the relationship between socioeconomic status & glycemic management in pediatric type 1 diabetes
Stanley JR, Clarke A, Shulman R, Mahmud F
Diabetes Technol Ther. Pub. online 21 Nov 2022.
Leggi
Diabetes and the COVID-19 pandemic
Khunti K, Valabhji J, Misra S
Diabetologia. Pub. online 23 Nov 2022.
Leggi
Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
Morton JI, Marquina C, Shaw JE et, al.
Diabetologia. Pub. online 21 Nov 2022.
Leggi
Exercise as a non-pharmacological intervention to protect pancreatic beta cells in individuals with type 1 and type 2 diabetes
Coomans de Brachène A, Scoubeau C, Musuaya AE, et al.
Diabetologia. Pub. online 19 Nov 2022
Leggi
HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus
Angel M, Petrosyan Y, Doyle MA, Cooper C
BMC Endocr Disord. 2022;22(1):277.
Leggi